Aeglea reports Phase I data for AEB1102

In March, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) reported top-line data from a Phase I trial to treat arginase 1 (ARG1) deficiency showing that IV AEB1102 was well tolerated and reduced blood arginine levels to normal levels. The open-label trial enrolled 2 adult females with moderate to severe neurocognitive and neurological deficits caused by ARG1 deficiency. Patients received up to 4 doses levels -- 0.015, 0.03, 0.06 and 0.1 mg/kg -- of IV AEB1102, with dose-escalation at 2-week intervals. Dosing was stopped when plasma arginine levels were reduced to <40 µM. At 168 hours post-dose, Aeglea said plasma arginine levels remained suppressed by 25-49% compared to pre-dose levels. Data were presented at the American College of Medical Genetics and Genomics meeting in Phoenix...